- Home
- EXFY vs VIGL Comparison
EXFY vs VIGL Comparison
Compare EXFY & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXFY
- VIGL
- Stock Information
- Founded
- EXFY 2008
- VIGL 2020
- Country
- EXFY United States
- VIGL United States
- Employees
- EXFY N/A
- VIGL N/A
- Industry
- EXFY Computer Software: Prepackaged Software
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- EXFY Technology
- VIGL Health Care
- Exchange
- EXFY Nasdaq
- VIGL Nasdaq
- Market Cap
- EXFY 150.3M
- VIGL 141.5M
- IPO Year
- EXFY 2021
- VIGL 2022
- Fundamental
- Price
- EXFY $2.93
- VIGL $3.20
- Analyst Decision
- EXFY Hold
- VIGL Buy
- Analyst Count
- EXFY 5
- VIGL 5
- Target Price
- EXFY $2.63
- VIGL $16.80
- AVG Volume (30 Days)
- EXFY 682.8K
- VIGL 49.7K
- Earning Date
- EXFY 11-07-2024
- VIGL 11-07-2024
- Dividend Yield
- EXFY N/A
- VIGL N/A
- EPS Growth
- EXFY N/A
- VIGL N/A
- EPS
- EXFY N/A
- VIGL N/A
- Revenue
- EXFY $137,440,000.00
- VIGL N/A
- Revenue This Year
- EXFY N/A
- VIGL N/A
- Revenue Next Year
- EXFY $7.39
- VIGL N/A
- P/E Ratio
- EXFY N/A
- VIGL N/A
- Revenue Growth
- EXFY N/A
- VIGL N/A
- 52 Week Low
- EXFY $1.24
- VIGL $2.47
- 52 Week High
- EXFY $3.00
- VIGL $6.80
- Technical
- Relative Strength Index (RSI)
- EXFY 80.16
- VIGL 37.10
- Support Level
- EXFY $1.82
- VIGL $3.52
- Resistance Level
- EXFY $3.00
- VIGL $3.75
- Average True Range (ATR)
- EXFY 0.17
- VIGL 0.20
- MACD
- EXFY 0.13
- VIGL -0.06
- Stochastic Oscillator
- EXFY 85.71
- VIGL 0.00
About EXFY Expensify Inc.
Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.